title: Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma.
abstract: Despite the recent success of MAPK signaling-targeted drugs in melanoma, the majority of patients with metastatic melanoma still undergo disease progression after initial tumor shrinkage indicating gradually developing therapy resistance. This review will give an overview on currently suggested concepts of resistance to MAPK pathway inhibitors in melanoma with particular focus on inter- and intraindividual as well as intratumor heterogeneity. The high plasticity of melanoma cells promotes both the clonal evolution of genetic resistance, for example, because of mutations in the MAPK or PI3K/AKT/PTEN pathways, and the emergence of cell phenotypes that functionally and metabolically overcome MAPK inhibition. Like a 'moving target', melanoma cells are shifting between different metabolic, cell cycle and differentiation states reflecting a highly dynamic potential to adapt to exogenous stressors including drugs. The introduction of MAPK inhibitors into the clinics has tremendously pushed the field of melanoma research not just because of the historic therapeutic success but also by providing a new tool to study human melanoma in its natural microenvironment.
authors.affiliation: University Hospital Essen, Department of Dermatology, Essen, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Roesch
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D018740:Genetic Heterogeneity; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors
references.citation: Genes Dev. 2006 Dec 15;20(24):3426-39
references.pmid: 17182868
references.citation: Nature. 2011 Nov 23;480(7377):387-90
references.pmid: 22113612
references.citation: Cancer Discov. 2012 Mar;2(3):227-35
references.pmid: 22448344
references.citation: Cancer Discov. 2014 Jan;4(1):61-8
references.pmid: 24265154
references.citation: Cell Metab. 2005 Jun;1(6):361-70
references.pmid: 16054085
references.citation: Mitochondrion. 2010 Nov;10(6):584-8
references.pmid: 20709626
references.citation: N Engl J Med. 2012 Feb 23;366(8):707-14
references.pmid: 22356324
references.citation: N Engl J Med. 2012 Jul 12;367 (2):107-14
references.pmid: 22663011
references.citation: Cancer Res. 2012 Oct 1;72(19):5035-47
references.pmid: 22865452
references.citation: Nature. 2010 Dec 16;468(7326):968-72
references.pmid: 21107320
references.citation: Oncogene. 2011 May 19;30(20):2307-18
references.pmid: 21278797
references.citation: Cancer Res. 2008 Jun 15;68(12):4853-61
references.pmid: 18559533
references.citation: Cancer Cell. 2013 Jun 10;23 (6):811-25
references.pmid: 23764003
references.citation: Cell. 2010 May 14;141(4):583-94
references.pmid: 20478252
references.citation: Nat Rev Clin Oncol. 2014 Feb;11(2):75-6
references.pmid: 24419300
references.citation: Cancer Discov. 2013 Dec;3(12 ):1378-93
references.pmid: 24104062
references.citation: Nat Med. 2013 Nov;19(11):1401-9
references.pmid: 24202393
references.citation: Nature. 2012 Jul 26;487(7408):505-9
references.pmid: 22763448
references.citation: Science. 2010 Dec 3;330(6009):1340-4
references.pmid: 21127244
references.citation: Biochim Biophys Acta. 2011 Jun;1807(6):552-61
references.pmid: 20955683
references.citation: Clin Cancer Res. 2013 Oct 15;19(20):5749-57
references.pmid: 23948972
references.citation: Nature. 2005 Jul 7;436(7047):117-22
references.pmid: 16001072
references.citation: Cancer Discov. 2012 May;2(5):414-24
references.pmid: 22588879
references.citation: Cell Rep. 2013 Sep 26;4(6):1090-9
references.pmid: 24055054
references.citation: Oncogene. 2012 May 10;31(19):2461-70
references.pmid: 21996743
references.citation: J Invest Dermatol. 2012 Jul;132(7):1850-9
references.pmid: 22437314
references.citation: N Engl J Med. 2010 Aug 26;363(9):809-19
references.pmid: 20818844
references.citation: Nat Commun. 2012 Mar 06;3:724
references.pmid: 22395615
references.citation: Nature. 2013 Feb 14;494(7436):251-5
references.pmid: 23302800
references.citation: Nature. 2012 Jul 26;487(7408):500-4
references.pmid: 22763439
references.citation: Cancer Cell. 2013 Jul 8;24(1):105-19
references.pmid: 23792190
references.citation: J Clin Oncol. 2011 Aug 1;29(22):3085-96
references.pmid: 21383288
references.citation: J Clin Oncol. 2013 May 10;31(14 ):1767-74
references.pmid: 23569304
references.citation: J Invest Dermatol. 2013 Jun;133(6):1601-9
references.pmid: 23321925
references.citation: Cell Death Differ. 2012 Dec;19(12 ):2029-39
references.pmid: 22858545
references.citation: Pigment Cell Melanoma Res. 2010 Dec;23(6):746-59
references.pmid: 20726948
references.citation: Oncotarget. 2013 Nov;4(11):1986-98
references.pmid: 24161908
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: Semin Cell Dev Biol. 2012 Jun;23 (4):381-8
references.pmid: 22285815
references.citation: Lancet Oncol. 2014 Mar;15(3):323-32
references.pmid: 24508103
references.citation: J Clin Invest. 2013 May;123(5):2155-68
references.pmid: 23543055
references.citation: Pigment Cell Melanoma Res. 2012 May;25(3):343-53
references.pmid: 22336146
references.citation: Clin Cancer Res. 2014 Apr 1;20(7):1965-77
references.pmid: 24463458
references.citation: Lancet. 2012 Jul 28;380(9839):358-65
references.pmid: 22735384
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6199-206
references.pmid: 19917835
references.citation: Nature. 2014 Apr 3;508(7494):118-22
references.pmid: 24670642
references.citation: Cancer Res. 2011 Aug 1;71(15):5067-74
references.pmid: 21803746
references.citation: Cancer Discov. 2014 Jan;4(1):94-109
references.pmid: 24265153
references.citation: Science. 2009 May 22;324(5930):1029-33
references.pmid: 19460998
references.citation: J Invest Dermatol. 2014 Feb;134(2):319-25
references.pmid: 24108405
references.citation: Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18226-31
references.pmid: 24145418
references.citation: Mol Cancer Res. 2014 May;12(5):795-802
references.pmid: 24520098
references.citation: Cancer Cell. 2010 Dec 14;18(6):683-95
references.pmid: 21156289
references.citation: Cancer Cell. 2013 Mar 18;23 (3):302-15
references.pmid: 23477830
references.citation: Cancer Res. 2008 Feb 1;68(3):650-6
references.pmid: 18245463
references.citation: Nature. 2012 Jan 26;483(7387):100-3
references.pmid: 22281684
references.citation: N Engl J Med. 2012 Nov;367 (18):1694-703
references.pmid: 23020132
references.citation: Nature. 2010 Dec 16;468(7326):973-7
references.pmid: 21107323
references.citation: Cell. 2010 Apr 2;141(1):69-80
references.pmid: 20371346
references.citation: Clin Cancer Res. 2013 Sep 1;19(17):4868-78
references.pmid: 23833299
references.citation: Cancer Res. 2012 Feb 15;72 (4):969-78
references.pmid: 22205714
references.citation: Nature. 2013 Dec 5;504(7478):138-42
references.pmid: 24185007